---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-001810"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2025-01-08T23:59:59+00:00"
generated_at: "2026-05-28T06:57:00.180298+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Jasper reports positive BEACON data: 240mg dose shows UAS7 drop of 26.6, 100% complete response at 8 weeks

## Summary
- Mean UAS7 change of -26.6 at 8 weeks in 240mg single-dose cohort (N=3); all patients achieved Complete Response (UAS7=0).
- Multiple dosing regimens ≥120mg showed UAS7 reduction >25 points; clinical responses as early as 1 week post-first dose.
- Serum tryptase reductions below lower limit of quantification observed; 100% of 240mg cohort at week 1.
- Favorable safety profile: no dose-limiting toxicities, infrequent low-grade c-Kit blockade events, no discontinuations.
- Registrational Phase 2b study in CSU expected to commence in second half of 2025; additional data by mid-2025.

## SEC filing metadata
- accession: 0001213900-25-001810
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2025-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390025001810/0001213900-25-001810-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390025001810/ea0227148-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-001810
- JSON: https://secwatch.observer/filing/0001213900-25-001810.json
- Plain text: https://secwatch.observer/filing/0001213900-25-001810.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.